Proficio Capital Partners LLC Invests $10.88 Million in Illumina, Inc. (NASDAQ:ILMN)

Proficio Capital Partners LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 81,381 shares of the life sciences company’s stock, valued at approximately $10,875,000. Proficio Capital Partners LLC owned approximately 0.05% of Illumina at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. Janney Montgomery Scott LLC grew its stake in shares of Illumina by 73.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company’s stock worth $858,000 after acquiring an additional 2,783 shares in the last quarter. KBC Group NV grew its position in Illumina by 2.1% during the third quarter. KBC Group NV now owns 42,516 shares of the life sciences company’s stock valued at $5,544,000 after buying an additional 859 shares during the period. Huntington National Bank grew its position in Illumina by 29.4% during the third quarter. Huntington National Bank now owns 515 shares of the life sciences company’s stock valued at $67,000 after buying an additional 117 shares during the period. Metis Global Partners LLC grew its position in Illumina by 9.1% during the third quarter. Metis Global Partners LLC now owns 3,575 shares of the life sciences company’s stock valued at $466,000 after buying an additional 299 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. grew its position in Illumina by 7.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,978 shares of the life sciences company’s stock valued at $649,000 after buying an additional 326 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Stephens restated an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Royal Bank of Canada reduced their price target on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday. Piper Sandler upped their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Finally, Citigroup dropped their price objective on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Trading Up 1.8 %

Shares of Illumina stock opened at $85.60 on Friday. The company’s 50-day moving average price is $113.52 and its 200-day moving average price is $129.88. The company has a market cap of $13.56 billion, a price-to-earnings ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.